Document is current
Any future updates will be listed below
-
Authors
Giannakopoulou, Eirini
Lehander, Madeleine
Virding Culleton, Stina
Yang, Weiwen
Li, Yingqian
Karpanen, Terhi http://orcid.org/0000-0002-2803-083X
Yoshizato, Tetsuichi
Rustad, Even H.
Nielsen, Morten Milek
Bollineni, Ravi Chand
Tran, Trung T.
Delic-Sarac, Marina
Gjerdingen, Thea Johanne
Douvlataniotis, Karolos
Laos, Maarja
Ali, Muhammad
Hillen, Amy http://orcid.org/0000-0002-8567-1545
Mazzi, Stefania
Chin, Desmond Wai Loon
Mehta, Adi
Holm, Jeppe Sejerø
Bentzen, Amalie Kai
Bill, Marie
Griffioen, Marieke http://orcid.org/0000-0002-3001-4441
Gedde-Dahl, Tobias
Lehmann, Sören
Jacobsen, Sten Eirik W. http://orcid.org/0000-0002-1362-3659
Woll, Petter S. http://orcid.org/0000-0002-2340-2526
Olweus, Johanna http://orcid.org/0000-0002-1898-3100
- License Information
-
More Information
Article History
Received: 16 November 2022
Accepted: 28 August 2023
First Online: 2 October 2023
Competing interests
: A patent application has been filed by the Oslo University Hospital institutional technology transfer office Inven2 protecting the TCR sequence (J.O. and E.G. are inventors). J.O. is on the scientific advisory board of Asgard Therapeutics and is a cofounder of T-Rx therapeutics, a company that aims to develop TCR T cell therapies. The other co-authors declare no competing interests.
